Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stromal cell therapy for refractory ulcerative proctitis in ulcerative colitis
2017-003524-75Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells in autoimmune colitis and ulcerative proctitis, sponsored by Leiden University Medical Center. Primary endpoints: Safety at 6 weeks, Tolerability and 1 more. Started Feb 2018; status: active.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
autoimmune colitisulcerative proctitis
Beyond the preview
Go deeper on 2017-003524-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003524-75.